These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21358336)

  • 1. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.
    Levy DE; Byfield SD; Comstock CB; Garber JE; Syngal S; Crown WH; Shields AE
    Genet Med; 2011 Apr; 13(4):349-55. PubMed ID: 21358336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.
    Malone KE; Daling JR; Doody DR; Hsu L; Bernstein L; Coates RJ; Marchbanks PA; Simon MS; McDonald JA; Norman SA; Strom BL; Burkman RT; Ursin G; Deapen D; Weiss LK; Folger S; Madeoy JJ; Friedrichsen DM; Suter NM; Humphrey MC; Spirtas R; Ostrander EA
    Cancer Res; 2006 Aug; 66(16):8297-308. PubMed ID: 16912212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk.
    Armstrong K; Weber B; Stopfer J; Calzone K; Putt M; Coyne J; Schwartz JS
    Am J Med Genet A; 2003 Mar; 117A(2):154-60. PubMed ID: 12567413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.
    McGuinness JE; Trivedi MS; Silverman T; Marte A; Mata J; Kukafka R; Crew KD
    Cancer Genet; 2019 Jun; 235-236():72-76. PubMed ID: 31078448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.
    Gal I; Gershoni Baruch R; Haber D; Dagan E; Eisenberg-Barzilai S; Zidan J; Friedman E
    Fam Cancer; 2004; 3(1):11-4. PubMed ID: 15131400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
    JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1/2 testing among young women with breast cancer in Massachusetts, 2010-2013: An observational study using state cancer registry and All-Payer claims data.
    Pace LE; Ayanian JZ; Wolf RE; Knowlton R; Gershman ST; Hawkins SS; Keating NL
    Cancer Med; 2022 Jul; 11(13):2679-2686. PubMed ID: 35312162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
    McCarthy AM; Bristol M; Domchek SM; Groeneveld PW; Kim Y; Motanya UN; Shea JA; Armstrong K
    J Clin Oncol; 2016 Aug; 34(22):2610-8. PubMed ID: 27161971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study.
    McCarthy AM; Bristol M; Fredricks T; Wilkins L; Roelfsema I; Liao K; Shea JA; Groeneveld P; Domchek SM; Armstrong K
    Cancer; 2013 Oct; 119(20):3596-603. PubMed ID: 23861169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline BRCA Mutation Rates in Latina Women Presenting for Gynecologic Oncology Care.
    Hong L; Gonzalez R; Unternaehrer J; Ioffe Y
    Gynecol Obstet Invest; 2020; 85(3):214-221. PubMed ID: 32203957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center.
    Abdallah N; Purrington KS; Tatineni S; Assad H; Petrucelli N; Simon MS
    Cancer Causes Control; 2023 Feb; 34(2):141-149. PubMed ID: 36370215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
    Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F
    Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
    Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH
    JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer.
    Susswein LR; Skrzynia C; Lange LA; Booker JK; Graham ML; Evans JP
    J Clin Oncol; 2008 Jan; 26(1):32-6. PubMed ID: 18165638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
    Jackson SA; Davis AA; Li J; Yi N; McCormick SR; Grant C; Fallen T; Crawford B; Loranger K; Litton J; Arun B; Vande Wydeven K; Sidani A; Farmer K; Sanders M; Hoskins K; Nussbaum R; Esserman L; Garber JE; Kaklamani VG;
    Cancer; 2014 May; 120(10):1557-64. PubMed ID: 24522996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.